Sakar Healthcare Limited — Investor Meet, 22-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sakar Healthcare delivered strong Q4 FY26 results: Revenue +42% YoY to INR71.10 Cr, EBITDA +67% to INR26.24 Cr (37% margin), PAT +91% to INR11.02 Cr. FY26 revenue grew 42% to INR251.74 Cr. Management targets 40% revenue growth in FY27, aiming for INR500 Cr in two years, primarily from oncology (60% of revenue, 65% from exports). The EU GMP Bavla oncology plant, under 30% utilization, offers substantial operating leverage. Growth drivers include accelerating tech transfers (e.g., Accord's INR50-100 Cr potential), increasing global dossier approvals, and API integration. Margins are projected to sustain or improve.